Levaquin, or levofloxacin, targets a broad spectrum of bacteria. Its primary mechanism involves inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes crucial for bacterial DNA replication and repair. This leads to bacterial cell death.
Gram-positive bacteria: Levaquin demonstrates activity against Streptococcus pneumoniae (including penicillin-resistant strains), Staphylococcus aureus (methicillin-susceptible strains), and various streptococcal species. However, resistance is a growing concern, particularly with S. aureus.
Gram-negative bacteria: Levaquin effectively targets Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa (though activity may vary), and Enterobacter species. Again, resistance patterns necessitate susceptibility testing.
Atypical bacteria: Levaquin is active against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila. This makes it valuable in treating community-acquired pneumonia where these pathogens are frequently involved.
Important Note: Always consult a physician or refer to current guidelines for specific recommendations on Levaquin use. Antibiotic resistance is a significant issue; therefore, empirical use should be minimized, and susceptibility testing is strongly recommended whenever possible. This information is for educational purposes only and does not constitute medical advice.
Specific Infections: Levaquin is often prescribed for respiratory tract infections (pneumonia, bronchitis), urinary tract infections, skin infections, and certain bone and joint infections. However, the choice of antibiotic should always be based on the pathogen identified and its susceptibility profile.
Adverse Effects: Like all antibiotics, Levaquin carries potential side effects, including tendon rupture, peripheral neuropathy, and CNS effects. Careful monitoring is necessary.
